Genmab Reports Strong Q3 2026 Growth Driven by DARZALEX and EPKINLY Sales
Genmab (GMAB) reported robust financial results for the first nine months of 2026, with total revenue reaching $3.238 billion, a 22% increase year-over-year. This growth was primarily fueled by significant royalty income from DARZALEX and Kesimpta, alongside strong sales performance from EPKINLY, which saw a 47% increase in global net sales. The company's adjusted operating profit rose 9% to $1.108 billion during the period. Management provided optimistic full-year 2026 guidance, projecting revenue between $4.325 billion and $4.525 billion, with expectations to land in the upper end of that range. Despite increased spending on manufacturing and launch readiness, Genmab maintains a strong cash position of $1.86 billion. Looking ahead, Genmab is focusing on clinical expansion and deleveraging its balance sheet following the Merus acquisition. Key pipeline assets like EPKINLY and Petosemtamab continue to show high commercial potential, with management reiterating ambitious peak sales targets for these programs.
Tickers: $AMGN $GMAB $JNJ $MRUS $NVS $SNY
Topics: earnings report financial guidance pharmaceuticals revenue growth